Genetic modifiers of Duchenne Muscular Dystrophy
Genetic modifiers of Duchenne Muscular Dystrophy
批准号:
10682505
负责人:
KEVIN M FLANIGAN
金额:
$93.22万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-05-15 至 2027-07-31
关键词:
20 year oldAffectAgeArchivesAwardBecker Muscular DystrophyBirthC-terminalCandidate Disease GeneCardiacCardiomyopathiesCessation of lifeClinicalClinical TrialsCollaborationsDNADataDatabasesDeoxyribonucleasesDiagnosisDiseaseDisease ProgressionDuchenne muscular dystrophyDystrophinEngineeringEnrollmentEuropeExonsFamilyFatty acid glycerol estersFibrosisFirst Independent Research Support and Transition AwardsFundingFutureGene ModifiedGene MutationGenesGeneticGenetic PolymorphismGenomic SegmentGenotypeGoalsGrantHi-CHypersensitivityLinkMagnetic Resonance ImagingMapsMeasuresMedical Care CostsMethodsModelingMolecularMorbidity - disease rateMusMuscleMuscle FibersMuscular DystrophiesMutationMyopathyNatural HistoryNecrosisOpen Reading FramesOutcomeParentsPathway interactionsPatientsPhenotypePrincipal InvestigatorProteinsQuantitative Trait LociRecontactsRecordsResearchResearch PersonnelResourcesSNP arraySNP genotypingSamplingSeveritiesSeverity of illnessSiblingsSignal TransductionSingle Nucleotide PolymorphismSiteSkeletal MuscleTestingTherapeutic InterventionThrombospondin 1United States National Institutes of HealthUpdateValidationVariantWalkingWorkcareercohortcoronary fibrosisdensitydisabilitydystrophinopathyexon skippinggene therapygenome-widegenomic dataheart functionin silicomalemicro-dystrophinnovelnovel strategiesnovel therapeuticsopportunity costparticipant enrollmentpatient stratificationphenotypic datapreservationprogramspromoterpsychologicpulmonary functionsocioeconomicstherapy outcometraitvalidation studies
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Duchenne muscular dystrophy (DMD) is a degenerative muscle disorder that affects
approximately 1:3500 to 1:5200 live male births caused by mutations in the X-linked DMD
gene. DMD gene mutations result in absence of the dystrophin protein in muscle fibers,
leading to myofiber necrosis, endomysial fibrosis, and fat replacement. It is a devastating
disorder, leading to loss of ambulation by age 12, and historically to death by age 20. The
psychological and socioeconomic effects on families are enormous; these include but are
not limited to the costs of medical care, opportunity costs for career and work, and the
psychological toll taken on parents and siblings. Our long-term goal is to understand which
genes modify disease progression and severity of DMD. Confirming a hypothesis derived
from a genetic modifier of muscular dystrophies in mice, we have recently used data from
patients enrolled in the United Dystrophinopathy Project (UDP) to demonstrate that
polymorphisms in the LTBP4 gene influence age at loss of ambulation. Our objective in
this project is to identify additional genetic modifiers of skeletal muscle, cardiac, and
ventilatory function, and our central hypothesis is that such modifiers can be identified
by use of the UDP database, a unique resource that contains detailed phenotypic data
and archived DNA samples from over 900 DMD patients. Our specific aims are to 1)
update and analyze phenotypic data within the UDP cohort, 2) map modifier traits by high-
density single nucleotide polymorphism arrays, and 3) validate newly identified putative
genetic modifiers. Validation will engage collaborating networks of investigators in the US
and Europe, who have additional natural history cohorts of DMD patients. At the
conclusion of these Aims, we will have gained new information about modifier genes
associated with the severity and progression of DMD.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.nmd.2017.11.007
发表时间:
2018-03
期刊:
NEUROMUSCULAR DISORDERS
影响因子:
2.8
作者:
[Waldrop, Megan A., Gumienny, Felecia, El Husayni, Saleh, Frank, Diane E., Weiss, Robert B., Flanigan, Kevin M.]
通讯作者:
Flanigan, Kevin M.
Beware the laboratory report: discrepancy in variant classification on reproductive carrier screening.
请注意实验室报告:生殖携带者筛查的变异分类存在差异。
DOI:
10.1038/gim.2017.174
发表时间:
2018
期刊:
Genetics in medicine : official journal of the American College of Medical Genetics
影响因子:
--
作者:
[Ramdaney,Aarti, Dunn,DianeM, Weiss,RobertB, Rose,NancyC]
通讯作者:
Rose,NancyC
DOI:
10.1371/journal.pone.0257164
发表时间:
2021
期刊:
PloS one
影响因子:
3.7
作者:
[Vieland VJ, Seok SC]
通讯作者:
Seok SC
DOI:
10.1371/journal.pone.0290336
发表时间:
2023
期刊:
PloS one
影响因子:
3.7
作者:
[]
通讯作者:
DOI:
10.1002/ana.25283
发表时间:
2018-08
期刊:
Annals of neurology
影响因子:
11.2
作者:
[Weiss RB, Vieland VJ, Dunn DM, Kaminoh Y, Flanigan KM, United Dystrophinopathy Project]
通讯作者:
United Dystrophinopathy Project
共 6 条
Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes
-
批准号:10660396
-
项目类别:
-
资助金额:$45.44万
-
财政年份:2023
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:9767664
-
项目类别:
-
资助金额:$144.31万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies
-
批准号:10017028
-
项目类别:
-
资助金额:$29.96万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Administrative Core
-
批准号:10017011
-
项目类别:
-
资助金额:$13.84万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:10016996
-
项目类别:
-
资助金额:$141.75万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:9353717
-
项目类别:
-
资助金额:$148.7万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:9194559
-
项目类别:
-
资助金额:$150.0万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
First-in-Human rAAVrh74.MCK.GALGT2 DMD Clinical Trial
-
批准号:8884256
-
项目类别:
-
资助金额:$26.31万
-
财政年份:2015
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:8847815
-
项目类别:
-
资助金额:$82.54万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:9057628
-
项目类别:
-
资助金额:$77.48万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:9320661
-
项目类别:
-
资助金额:$77.48万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:10522759
-
项目类别:
-
资助金额:$94.62万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:8761968
-
项目类别:
-
资助金额:$98.77万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8267606
-
项目类别:
-
资助金额:$87.96万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8733204
-
项目类别:
-
资助金额:$120.48万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIIB by Systemic Gene Delivery
-
批准号:8701736
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8500478
-
项目类别:
-
资助金额:$120.72万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8109732
-
项目类别:
-
资助金额:$89.0万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
CLINICAL TRIAL: NONSENSE-MUTATION-MEDIATED DUCHENNE MUSCULAR DYSTROPHY
-
批准号:7718520
-
项目类别:
-
资助金额:$2.31万
-
财政年份:2008
-
负责人:KEVIN M FLANIGAN
-
依托单位:
STUDY OF INHERITED NEUROLOGICAL DISEASES
-
批准号:7718503
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2008
-
负责人:KEVIN M FLANIGAN
-
依托单位:
海外基金